Clinical and Economic Burden of Pneumococcal Disease Due to Serotypes Contained in Current and Investigational Pneumococcal Conjugate Vaccines in Children Under Five Years of Age

[11] Liu L(2018)Rapid increase in non-vaccine serotypes causing invasive pneumococcal disease in England and Wales, 2000–17: a prospective national observational cohort study Lancet Infect Dis 168 5072-4629

[12] Chu Y(2015)Impact of the pneumococcal conjugate vaccines on invasive pneumococcal disease in France, 2001–2012 Vaccine 59 4623-163

[13] Henriques-Normark B(2009)Pneumococcal serotypes and mortality following invasive pneumococcal disease: a population-based cohort study PLoS Med 33 155-642

[14] Tuomanen EI(2014)Trends in otitis media-related health care use in the United States, 2001–2011 JAMA Pediatr 33 637-924

[15] Ganaie F(2021)Effectiveness of the seven- and thirteen valent pneumococcal conjugate vaccines against vaccine-serotype otitis media Clin Infect Dis 369 918-4355

[16] Saad JS(2014)Near-elimination of otitis media caused by 13-valent pneumococcal conjugate vaccine (PCV) serotypes in southern Israel shortly after sequential introduction of 7-valent/13-valent PCV Clin Infect Dis 33 4349-420

[17] McGee L(2015)Impact of pneumococcal conjugate vaccines on childhood otitis media in the United Kingdom Vaccine 58 417-67

[18] van Tonder AJ(2015)Impact of PCV7/PCV13 introduction on community-acquired alveolar pneumonia in children <5 years Vaccine 32 e58-78

[19] Bentley SD(2013)hospitalizations for pneumonia after a decade of pneumococcal vaccination N Engl J Med 12 71-378

[20] Lo SW(2014)Changes in childhood pneumonia and infant mortality rates following introduction of the 13-valent pneumococcal conjugate vaccine in Nicaragua Pediatr Infect Dis J 7 368-656

[11] Liu L(2018)Rapid increase in non-vaccine serotypes causing invasive pneumococcal disease in England and Wales, 2000–17: a prospective national observational cohort study Lancet Infect Dis 168 5072-4629

[12] Chu Y(2015)Impact of the pneumococcal conjugate vaccines on invasive pneumococcal disease in France, 2001–2012 Vaccine 59 4623-163

[13] Henriques-Normark B(2009)Pneumococcal serotypes and mortality following invasive pneumococcal disease: a population-based cohort study PLoS Med 33 155-642

[14] Tuomanen EI(2014)Trends in otitis media-related health care use in the United States, 2001–2011 JAMA Pediatr 33 637-924

[15] Ganaie F(2021)Effectiveness of the seven- and thirteen valent pneumococcal conjugate vaccines against vaccine-serotype otitis media Clin Infect Dis 369 918-4355

[16] Saad JS(2014)Near-elimination of otitis media caused by 13-valent pneumococcal conjugate vaccine (PCV) serotypes in southern Israel shortly after sequential introduction of 7-valent/13-valent PCV Clin Infect Dis 33 4349-420

[17] McGee L(2015)Impact of pneumococcal conjugate vaccines on childhood otitis media in the United Kingdom Vaccine 58 417-67

[18] van Tonder AJ(2015)Impact of PCV7/PCV13 introduction on community-acquired alveolar pneumonia in children <5 years Vaccine 32 e58-78

[19] Bentley SD(2013)hospitalizations for pneumonia after a decade of pneumococcal vaccination N Engl J Med 12 71-378

[20] Lo SW(2014)Changes in childhood pneumonia and infant mortality rates following introduction of the 13-valent pneumococcal conjugate vaccine in Nicaragua Pediatr Infect Dis J 7 368-656